System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Lionel Karlin is an expert in Hematology at Centre Hospitalier Lyon Sud (France). As of October 2026, ScienceLeadR ranks Lionel Karlin in the top 1% of experts worldwide for Multiple Myeloma, Hemostatic Disorders and Paraproteinemias. Lionel Karlin has authored 430 publications, the most recent in 2026, and is an investigator in 82 clinical trials, 25 of them ongoing. SLR score: 2,301 (community average: 125). How the SLR is computed.

LeadR Profile

Lionel Karlin Centre Hospitalier Lyon Sud France
2 301 ScienceLeadR Reputation 2301

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Immunology - Cardiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2010 - 2026
Source: PubMed

Hospices Civils de Lyon

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 430

Citations

Citations: 18 352 1st author: 13 Last author: 4 Unique author: 4

Main journals

Blood 143
CL LYMPH MYELOM LEUK 39
J Clin Oncol 34
Haematologica 24
Hemasphere 23

Best Journals

J Clin Oncol 20
N Engl J Med 11
Lancet Oncol 8

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.
PMID 42897348 — genes, epigenomics, molecular biology, dexamethasone, multiple myeloma, neoplasm, residual, therapeutics		Nat Med Top journal20260
Supportive Care in Multiple Myeloma: Evidence-Based Recommendations From the Intergroupe Francophone du Myélome (IFM).
PMID 42864252 — cells, quality of life, antibodies, lymphoma, multiple myeloma, therapeutics, antibodies, bispecific, receptors, antigen, t-cell		Clin Lymphoma Myeloma Leuk20260
Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05).
PMID 42835780 — multiple myeloma, transplants		Hemasphere20260
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
PMID 42669079 — language, multiple myeloma		Future Oncol20260
Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results.
PMID 42607072 — research design, bone marrow, blood, serum, progression-free survival, predictive value of tests, maintenance, multiple myeloma		Blood20260

Clinical Studies 82

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Sub-Investigator: 1

By phase:

Phase 3 45
Phase 2 15
Phase 1 8
N/A 7
Phase 1/Phase 2 6
Phase 2/Phase 3 1

By status:

Completed 33
Active not recruiting 20
Recruiting 14
Terminated 7
Unknown 5
Not yet recruiting 3

By type:

Interventional 78
Observational 4

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 2
multicentric5to9 6
multicentricup10 69

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

25 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase 3 Randomized Study Comparing JNJ 79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
2025-523815-12-00 — multiple myeloma, lenalidomide, therapeutics		Phase 3Not yet recruiting2026
Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Previously Treated Multiple Myeloma
2025-524028-23-00 — safety, dexamethasone, multiple myeloma, therapeutics		Phase 3Not yet recruiting2026
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal DR) versus Daratumumab SC Lenalidomide and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy
2023-503442-30-00 — cells, microscopy, electron, scanning transmission, dexamethasone, stem cells, multiple myeloma, lenalidomide, transplants, therapeutics		Phase 3Active not recruiting2022
A phase 3 open label controlled randomized study of newly diagnosed multiple myeloma treatment designed to evaluate the efficacy and safety of the elranatamab lenalidomide combination as a replacement for chemotherapy followed by autologous stem cell transplant in the consolidation phase and to compare elranatamab with standard of care in the maintenance phase (ElLen IFM 2025 01)
2024-516418-39-00 — cells, safety, microscopy, electron, scanning transmission, stem cells, drug therapy, maintenance, multiple myeloma, lenalidomide, transplants, therapeutics, chemotherapy		Phase 3Recruiting2025
A Phase 3 Study Comparing JNJ 79635322 and an anti BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma
2025-522007-18-00 — multiple myeloma, therapeutics		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS